This interview with an EU-based KOL provides insights into current prescribing habits for HIV treatment, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies. Key assets highlighted include Biktarvy, Sunlenca, dolutegravir-based compounds (Dovato/Juluca/Tivicay/Triumeq), Pfieltro, Selzentry, Rukobia, Kaletra, Prezista, Reyataz, islatravir, Cabenuva, Norvir, Prezcobix, Vemlidy, Viread, MK-8591A, MK-8591D, and bictegravir + lenacapavir. 

This interview was conducted on 9 September 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.